ARQT (STOCKS)
Arcutis Biotherapeutics, Inc. Common Stock
$24.180000
-0.030000 (-0.12%)
Prev close: $24.210000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Todd Franklin Watanabe
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,989.20M
- Employees
- 342
- P/E (TTM)
- -173.05
- P/B (TTM)
- 15.76
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
8
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.13 | $0.12 | +0.0143 | +12.36% |
|
Sep 2025 (Q3)
|
$0.06 | $-0.10 | +0.1619 | +158.88% |
|
Jun 2025 (Q2)
|
$-0.13 | $-0.16 | +0.0313 | +19.40% |
|
Mar 2025 (Q1)
|
$-0.20 | $-0.21 | +0.0142 | +6.63% |
Financial Statements
| Revenues | $376.07M |
| Benefits Costs and Expenses | $388.30M |
| Cost Of Revenue | $36.70M |
| Costs And Expenses | $388.30M |
| Gross Profit | $339.38M |
| Operating Expenses | $351.60M |
| Selling, General, and Administrative Expenses | $274.55M |
| Research and Development | $77.05M |
| Operating Income/Loss | -$12.23M |
| Income/Loss From Continuing Operations After Tax | -$16.14M |
| Income/Loss From Continuing Operations Before Tax | -$12.23M |
| Income Tax Expense/Benefit | $1.17M |
| Income Tax Expense/Benefit, Current | $1.12M |
| Income Tax Expense/Benefit, Deferred | $54.00K |
| Net Income/Loss | -$16.14M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$16.14M |
| Net Income/Loss Available To Common Stockholders, Basic | -$16.14M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.13 |
| Diluted Earnings Per Share | -$0.13 |
| Basic Average Shares | 127,234,000 |
| Diluted Average Shares | 127,234,000 |
| Assets | $432.97M |
| Current Assets | $411.23M |
| Inventory | $22.63M |
| Other Current Assets | $388.60M |
| Noncurrent Assets | $21.74M |
| Fixed Assets | $1.04M |
| Intangible Assets | $14.81M |
| Other Non-current Assets | $5.89M |
| Liabilities | $243.49M |
| Current Liabilities | $129.84M |
| Accounts Payable | $12.53M |
| Wages | $20.53M |
| Other Current Liabilities | $96.78M |
| Noncurrent Liabilities | $113.66M |
| Long-term Debt | $108.96M |
| Other Non-current Liabilities | $4.70M |
| Equity | $189.48M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $189.48M |
| Liabilities And Equity | $432.97M |
| Net Cash Flow From Operating Activities | -$5.63M |
| Net Cash Flow From Operating Activities, Continuing | -$5.63M |
| Net Cash Flow From Investing Activities | -$30.25M |
| Net Cash Flow From Investing Activities, Continuing | -$30.25M |
| Net Cash Flow From Financing Activities | $6.97M |
| Net Cash Flow From Financing Activities, Continuing | $6.97M |
| Net Cash Flow | -$28.91M |
| Net Cash Flow, Continuing | -$28.91M |
| Comprehensive Income/Loss | -$16.18M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$16.18M |
| Other Comprehensive Income/Loss | -$16.18M |
| Other Comprehensive Income/Loss Attributable To Parent | -$37.00K |